ProCE Banner Activity

My Thoughts on Recently Approved Therapies for EGFR Exon 20 Insertion Mutation–Positive Advanced NSCLC

Clinical Thought
Get expert insights on the use of 2 recently approved therapies for your patients with advanced NSCLC and EGFR exon 20 insertion mutations.

Released: October 06, 2021

Expiration: October 05, 2022

No longer available for credit.

Share

Faculty

Joshua Sabari

Joshua Sabari, MD

Assistant Professor of Medicine
Thoracic Medical Oncology
NYU Langone Health
Perlmutter Cancer Center
NYU Grossman School of Medicine
New York, NY

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Pharmaceutica NV

Faculty Disclosure

Primary Author

Joshua Sabari, MD

Assistant Professor of Medicine
Thoracic Medical Oncology
NYU Langone Health
Perlmutter Cancer Center
NYU Grossman School of Medicine
New York, NY

Joshua Sabari, MD, has disclosed that he has received consulting fees from AstraZeneca, Genentech, Janssen, Navire, PharmaMar, Regeneron, Sanofi Genzyme, and Takeda.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Lobna M. Eldasher, PharmD

Lobna M. Eldasher, PharmD, has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.